Relevant bibliographies by topics / HIV Drug Resistance

Academic literature on the topic 'HIV Drug Resistance'

Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV Drug Resistance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HIV Drug Resistance"

1

Clavel, François, and Allan J. Hance. "HIV Drug Resistance." New England Journal of Medicine 350, no. 10 (March 4, 2004): 1023–35. http://dx.doi.org/10.1056/nejmra025195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Richman, D. D. "HIV Drug Resistance." Annual Review of Pharmacology and Toxicology 33, no. 1 (April 1993): 149–64. http://dx.doi.org/10.1146/annurev.pa.33.040193.001053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

RICHMAN, DOUGLAS D. "HIV Drug Resistance." AIDS Research and Human Retroviruses 8, no. 6 (June 1992): 1065–71. http://dx.doi.org/10.1089/aid.1992.8.1065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schmit, Jean-Claude. "HIV drug resistance." HIV Clinical Trials 3, no. 3 (May 2002): 225–26. http://dx.doi.org/10.1310/kmkn-ke48-2gwu-g0he.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "HIV Drug Resistance." New England Journal of Medicine 350, no. 26 (June 24, 2004): 2720–21. http://dx.doi.org/10.1056/nejm200406243502621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Richman, Douglas D. "HIV DRUG RESISTANCE." AIDS 8, Supplement 4 (November 1994): S3. http://dx.doi.org/10.1097/00002030-199411004-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nadia, Rizka, Dwitya Elvira, and Raveinal. "HIV Drug Resistance Mutations." Bioscientia Medicina : Journal of Biomedicine and Translational Research 6, no. 7 (May 27, 2022): 2006–13. http://dx.doi.org/10.37275/bsm.v6i7.547.

Full text
Abstract:
ART resistance, according to WHO, is the presence of one or more mutations in HIV that reduces the ability of certain drugs or drug groups to inhibit viral replication. According to the 2019 HIV Drug Resistance Report issued by the WHO, the prevalence of Antiretroviral Therapy (ART) drug resistance is 3%-29%. The prevalence of HIV drug resistance varies by country. In developed countries, the prevalence ranges from 6.6% to 11%. There are two types of resistance to ART: primary and secondary resistance. Primary resistance reflects the acquisition of drug-resistant strains in individuals who have recently been infected and have not received therapy. Secondary resistance occurs after treatment with ART. Resistance to antiretroviral therapy, mainly NRTIs, NNRTIs, and protease inhibitors, is caused by continuous inhibition of the HIV reverse transcriptase enzyme. World Health Organization (WHO) has recommended two NRTIs plus Lopinavir or Atazanavir as a second-line regimen for individuals who have failed treatment with efavirenz or dolutegravir; two NRTIs plus Darunavir and Lopinavir plus Raltegravir are recommended as an alternative due to cost constraints and the fact that Darunavir is unstable in moderately hot conditions.
APA, Harvard, Vancouver, ISO, and other styles
8

Salvana, Edsel Maurice, Brian Schwem, Christine Penalosa, Geraldine Arevalo, Nina Dungca, Jodor Lim, Katerina Leyritana, and Raul Destura. "HIV Transmitted Drug Resistance in the Philippines: The Case for Baseline Genotyping and Drug Resistance Testing." Open Forum Infectious Diseases 4, suppl_1 (2017): S423. http://dx.doi.org/10.1093/ofid/ofx163.1064.

Full text
Abstract:
Abstract Background The Philippines has one of the fastest growing HIV epidemics in the world. Parallel to the increase is a shift in HIV subtype from B to CRF01_AE. No transmitted drug resistance (TDR) surveillance has ever been conducted. With the widespread rollout of antiretrovirals and the limited repertoire of 6 drugs (tenofovir, lamivudine, zidovudine, nevirapine, efavirenz, lopinavir/ritonavir) makes TDR monitoring imperative. In addition, a high rate of hepatitis B (HBV) co-infection (17%) in the general population raises the risk of TDR with prior NRTI monotherapy. Methods Following IRB approval, we performed TDR surveillance at the Philippine General Hospital, one of the largest tertiary referral centers in the country. Treatment-naïve patients had their HIV RT and PR genes sequenced using WHO approved-protocols for HIV genotyping. Generated sequences were analyzed using the Stanford Drug Resistance Database. Pertinent demographic and clinical data were collected. The current results represent year 1 of the study. Results 95 treatment naïve patients were analyzed. Median age was 30 years (range 20–68). There were 88 males and 7 females. Median CD4 count was 90 cells/mL (range 0–936) and median viral load was 1792000 copies/mL. 18 patients were co-infected with HBV, but all denied previous HBV treatment. Conclusion The TDR rate for HIV in the Philippines is 6.3%. This is above the threshold for recommending baseline TDR genotyping for all local HIV patients. All HIV with TDR were subtype CRF01_AE, and this may signal a higher risk of TDR as the epidemic shifts further to a non-B subtype. Disclosures E. M. Salvana, Merck: Scientific Advisor and Speaker’s Bureau, Consulting fee and Speaker honorarium
APA, Harvard, Vancouver, ISO, and other styles
9

Tilghman, MW, J. Pérez-Santiago, G. Osorio, SJ Little, DD Richman, WC Mathews, RH Haubrich, and DM Smith. "Community HIV-1 drug resistance is associated with transmitted drug resistance." HIV Medicine 15, no. 6 (January 12, 2014): 339–46. http://dx.doi.org/10.1111/hiv.12122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lazzari, Stefano, Annapaola de Felici, Howard Sobel, and Silvia Bertagnolio. "HIV Drug Resistance Surveillance." AIDS 18, Supplement 3 (June 2004): S49—S53. http://dx.doi.org/10.1097/00002030-200406003-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "HIV Drug Resistance"

1

Lalonde, Matthew Scott. "HIV Drug Resistance Polymorphism Analysis Using Ligase Discrimination." Case Western Reserve University School of Graduate Studies / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=case1244059520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Svedhem, Johansson Veronica. "Kinetics of HIV-1 drug resistance mutations in vivo /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-671-9/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lindström, Anna. "Resistance to antiviral drugs in HIV and HBV /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-239-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chamberlain, Philip Paul. "Structural mechanisms of drug resistance for HIV reverse transcriptases." Thesis, University of Oxford, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.403941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Beerenwinkel, Niko [Verfasser]. "Computational Analysis of HIV Drug Resistance Data / Niko Beerenwinkel." Aachen : Shaker, 2004. http://d-nb.info/1170545238/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Exner, Natalie Mae. "Surveillance Methods for Monitoring HIV Incidence and Drug Resistance." Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11444.

Full text
Abstract:
Disease surveillance is the continuous collection, analysis, and interpretation of health-related data. Information gained from routine HIV disease surveillance is vital to national program managers deciding to implement new prevention or treatment programs. In this dissertation, we describe methods for estimation of HIV incidence and the prevalence of HIV drug resistance.
APA, Harvard, Vancouver, ISO, and other styles
7

Detsika, Maria G. "Evolution of minority species of HIV harbouring drug resistance." Thesis, University of Liverpool, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.428256.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Thao, Vu Phuong. "Transmitted and acquired HIV drug resistance in Viet Nam." Thesis, University of Oxford, 2015. https://ora.ox.ac.uk/objects/uuid:61bd161b-b561-47e1-88b2-86eea11d313f.

Full text
Abstract:
The roll-out of antiretroviral therapy (ART) in Viet Nam along with limited resources for treatment monitoring are expected to be accompanied by the emergence of transmitted and acquired drug resistance. Drug resistance challenges the success of ART program and the efforts to curb the HIV epidemic in Viet Nam. Understanding factors that impact treatment outcome and prevalence and patterns of drug resistance provides imperative information for strategic and effective management. The first part of this thesis aims to study the prevalence and patterns of transmitted drug resistance (TDR) in ART-naïve patients. TDR prevalence was detected in 6.4% of ARV-naïve patients with HIV-associated tuberculous meningitis initiating ART in Ho Chi Minh City (HCMC) from 2005-2007. This rate is lower than that in developed countries and is comparable to TDR rates reported in similar resource-limited countries. Pattern of TDR reflected the standard first-line ART regimens with nucleotide and non-nucleotide reverse transcriptase inhibitors in Viet Nam. The second part of this thesis aims to investigate factors that impact treatment outcome and drug resistance in second-line ART in Viet Nam. In a cohort of adult patients on second-line ART at the Hospital for Tropical Diseases, rate of clinical and/or immunological failure was 18.2% after a median follow up of 29 months. Older age, history of injecting drug use, lower CD4 count at second-line ART initiation, suboptimal ART adherence, and previous protease inhibitor (PI) use independently predicted treatment failure. Prevalence of virological failure (HIV RNA >1000 copies/mL as recommended by the 2013WHO guidelines) in patients who survived and were in active follow up was 9.5%, and high viral load, non-adherence and previous PI use were independent predictors for virological failure to second-line ART. 64% of patients with virological failure carried major PI mutations. Cross-resistance to third-line medications was higher than reported in other studies with cross resistance to ETR, TPV, and DRV of 55%, 45%, and 27% patients, respectively. This information informs selection of appropriate third-line ART regimen for patients failing second-line ART in Viet Nam. In conclusion, the work of this thesis provides important data on TDR in the chronically HIV-infected population in Viet Nam, provides, for the first time, data on treatment outcome to lopinavir-based second-line ART in the presence of extensive NRTI drug resistance, and identifies modifying risk factors to improve treatment outcomes in Viet Nam. Strategies to diagnose treatment failure accurately, to switch therapy timely, and to provide targeted adherence support will improve the outcomes of patients. Continued surveillance of TDR should be performed to assure the effectiveness of ART at the population level. Cost-effectiveness studies should be conducted in order to provide evidence for policy makers to decide whether to apply baseline genotypic testing and viral load monitoring in a resource limited country like Viet Nam. Prospective studies are needed to study the validity of WHO immunological/clinical criteria in defining virological treatment failure in PI-based second-line ART.
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Qi. "Computational analysis of HIV-1 evolution and drug resistance." Diss., Restricted to subscribing institutions, 2008. http://proquest.umi.com/pqdweb?did=1779690471&sid=1&Fmt=2&clientId=1564&RQT=309&VName=PQD.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Johansson, Veronica Svedhem. "Kinetics of HIV-1 drug resistance mutations in vivo." Stockholm : Karolinska Institutet, 2006. http://diss.kib.ki.se/2006/91-7140-671-9/thesis.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "HIV Drug Resistance"

1

National AIDS and STDs Control Programme (Kenya). The Kenya HIV drug resistance country report, 2010-2011. Nairobi: National AIDS & STI Controp Programme, NASCOP, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

HIV Drug Resistance Technical Working Group (Namibia). Report on early warning indicators of HIV drug resistance in Namibia, 2014. Windhoek: Republic of Namibia, Ministry of Health and Social Services, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

National AIDS and STDs Control Programme (Kenya). National HIV drug resistance prevention, monitoring, and surveillance plan: FY 2008-2012. Nairobi, Kenya: National AIDS/STI Control Program, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Subdivision, Namibia Ministry of Health and Social Services Directorate of Special Programmes Response Monitoring &. Evaluation. Report on the 2010 HIV drug resistance survey: Population-based monitoring of HIV drug resistance emerging during treatment and related programme factors in sentinel antiretroviral therapy sites in Namibia. Windhoek: Directorate of Special Programmes, Response Monitoring & Evaluation Subdivision, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Namibia. Ministry of Health and Social Services. Directorate of Special Programmes. Response Monitoring & Evaluation Subdivision. Report of the 2006 Namibia HIV Drug Sensitivity Survey. Windhoek, Namibia: Directorate of Special Programmes, Division Expanded National HIV/AIDS Coordination, Subdivision: Response Monitoring & Evaluation, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Namibia. Ministry of Health and Social Services. The Republic of Namibia HIV drug resistance surveillance strategy, 2013/2014-2017/2018. Windhoek: Republic of Namibia, Ministry of Health and Social Services, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, ed. Addressing the threat of drug-resistant tuberculosis: A realistic assessment of the challenge : workshop summary. Washington, D.C: National Academies Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Esté, José Andrés. Mode of action and development of resistance to human immunodeficiency virus inhibitors that are targeted at early stages of infection. Leuven, Belgium: Leuven University Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Huemer, Richard P. The natural health guide to beating the supergerms and other infections, including colds, flus, ear infections, and even HIV: Use vitamins and nutrients to turn your body into the ultimate germ killer. Edited by Challem Jack. New York: Pocket Books, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

World Health Organization (WHO). Management of MDR-TB: A field guide, a companion document to Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "HIV Drug Resistance"

1

Cane, Patricia. "HIV Drug Resistance Testing." In Diagnostic Virology Protocols, 123–32. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-817-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Doyon, Louise, Robert Elston, and Pierre R. Bonneau. "Resistance to HIV-1 Protease Inhibitors." In Antimicrobial Drug Resistance, 477–92. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Han, Ying-Shan, Thibault Mesplède, and Mark A. Wainberg. "HIV-1 Resistance to Integrase Inhibitors." In Antimicrobial Drug Resistance, 559–64. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46718-4_37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mayers, Douglas L. "Clinical Implications of HIV-1 Drug Resistance." In Antimicrobial Drug Resistance, 1049–60. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-595-8_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mayers, Douglas L., and John D. Baxter. "Clinical Implications of HIV-1 Drug Resistance." In Antimicrobial Drug Resistance, 1213–25. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-47266-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Elston, Robert, and Pierre R. Bonneau. "Resistance to HIV Non-Nucleoside Reverse Transcriptase Inhibitors." In Antimicrobial Drug Resistance, 461–75. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Melby, Thomas, Gabrielle Heilek, Nick Cammack, and Michael L. Greenberg. "Resistance to Enfuvirtide and Other HIV Entry Inhibitors." In Antimicrobial Drug Resistance, 493–506. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Herman, Brian D., Robert A. Domaoal, Maryam Ehteshami, and Raymond F. Schinazi. "Resistance Mechanisms to HIV-1 Nucleoside Reverse Transcriptase Inhibitors." In Antimicrobial Drug Resistance, 503–19. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46718-4_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sluis-Cremer, Nicolas. "HIV-1 Resistance to the Nonnucleoside Reverse Transcriptase Inhibitors." In Antimicrobial Drug Resistance, 521–33. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46718-4_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Venner, Colin M., Annette N. Ratcliff, Mathieu Coutu, Andrés Finzi, and Eric J. Arts. "HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance." In Antimicrobial Drug Resistance, 545–57. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46718-4_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HIV Drug Resistance"

1

Xiaxia Yu, Robert W. Harrison, and Irene T. Weber. "HIV drug resistance prediction using multiple regression." In 2013 IEEE 3rd International Conference on Computational Advances in Bio and Medical Sciences (ICCABS). IEEE, 2013. http://dx.doi.org/10.1109/iccabs.2013.6629203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kai, Masaaki, and Qinchang Zhu. "Convenient drug-resistance testing of HIV mutants." In 1st International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2015. http://dx.doi.org/10.3390/ecmc-1-a030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Faedo, Ivan, Silvia Martorano Raimundo, Ezio Venturino, Theodore E. Simos, George Psihoyios, and Ch Tsitouras. "A Mathematical Model for HIV Drug-Resistance." In ICNAAM 2010: International Conference of Numerical Analysis and Applied Mathematics 2010. AIP, 2010. http://dx.doi.org/10.1063/1.3498583.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Baltasar Marchueta, Maider. "Predicting HIV drug resistance using machine learning." In MOL2NET'22, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 8th ed. - MOL2NET: FROM MOLECULES TO NETWORKS. Basel, Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/mol2net-08-12473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cheng, Betty Y., and Jaime G. Carbonell. "Automatic Detection of HIV Drug Resistance-Associated Mutations." In 2010 International Conference on Machine Learning and Applications (ICMLA). IEEE, 2010. http://dx.doi.org/10.1109/icmla.2010.83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Potter, R. Brian, and Sorin Draghici. "A SOFM Approach to Predicting HIV Drug Resistance." In Proceedings of the Pacific Symposium. WORLD SCIENTIFIC, 2001. http://dx.doi.org/10.1142/9789812799623_0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yu, Xiaxia, Irene Weber, and Robert Harrison. "Sparse Representation for HIV-1 Protease Drug Resistance Prediction." In Proceedings of the 2013 SIAM International Conference on Data Mining. Philadelphia, PA: Society for Industrial and Applied Mathematics, 2013. http://dx.doi.org/10.1137/1.9781611972832.38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

de Araújo, Luciano Vieira, Ester C. Sabino, and João Eduardo Ferreira. "HIV drug resistance analysis tool based on process algebra." In the 2008 ACM symposium. New York, New York, USA: ACM Press, 2008. http://dx.doi.org/10.1145/1363686.1364001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Detecting Interacting Mutation Clusters in HIV-1 Drug Resistance." In International Conference on Bioinformatics Models, Methods and Algorithms. SciTePress - Science and and Technology Publications, 2013. http://dx.doi.org/10.5220/0004238800340043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bondarenko, Vasily, Irina Buynevich, Andrey Holyavkin, Svetlana Goponyako, and Nkolaj Burinsky. "Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2762.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "HIV Drug Resistance"

1

Chen, Jiankun, Yingming Gu, Lihong Yin, Minyi He, Na Liu, Yue Lu, Changcai Xie, Jiqiang Li, and Yu Chen. Network meta-analysis of curative efficacy of different acupuncture methods on obesity combined with insulin resistance. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0075.

Full text
Abstract:
Review question / Objective: Population：Patients diagnosed as obesity with insulin resistance. Obesity reference: Consensus of experts on the Prevention and treatment of adult obesity in China in 2011 and Consensus of Chinese experts on medical nutrition therapy for overweight/obesity in 2016 were developed by the Obesity Group of Chinese Society of Endocrinology(CSE); BMI≥28. IR reference: According to the Expert opinions on insulin resistance evaluation published by Chinese Diabetes Society, HOMA-IR≥2.68 is regarded as the standard for the diagnosis of IR. Regardless of age, gender and course of disease. Patients diagnosed as obesity with insulin resistance. Intervention：Any kind of acupuncture, moxibustion, acupuncture+moxibustion, warm acupuncture, electropuncture, auricular point, acupoint application and acupoint catgut embedding. Comparison：Other acupuncture treatments, Drug therapy or blank control. Outcome：Primary outcomes: ①Fasting blood-glucose (FBG); ②Fasting serum insulin (FINS); ③Homeostasis model assessment-IR (HOMA-IR); ④Body Mass Index (BMI). Secondary outcomes: ①Waistline; ②Waist-hip ratio;③Triglyceride (TG); ④Total cholesterol (TC); ⑤High-density lipoprotein (HDL); ⑥Low-density lipoprotein (LDL). Study: Randomized controlled trials (RCTs) of different acupuncture methods in the treatment on obesity with insulin resistance, blind method and language are not limited. Randomized controlled trials (RCTs).
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'HIV Drug Resistance' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography